DLOC BIOSYSTEMS LTD

Executive Summary

DLOC BIOSYSTEMS LTD is an early-stage biotechnology start-up showing typical financial distress symptoms such as negative working capital and equity due to high R&D investment. While the company depends on related-party funding, it must strengthen liquidity and accelerate commercialization to improve its financial wellness. With strategic funding and operational focus, the company has potential to stabilize and grow.

DLOC BIOSYSTEMS LTD - Analysis Report

Company Number: 14670245

Analysis Date: 2025-07-29 18:02 UTC

Financial Health Assessment for DLOC BIOSYSTEMS LTD

---

1. Financial Health Score: D (Distressed Start-Up)

Explanation:
The company is in the very early stage of its lifecycle, having incorporated in February 2023 and filed its first accounts for the period ending February 2024. The financials show a significant net current liability position and negative equity resulting from accumulated losses. This indicates the company is currently operating with a financial deficit, typical for a start-up in heavy development or research phases. The "D" grade reflects the presence of financial distress symptoms but also acknowledges the nascent stage where investment and losses are expected as the business grows.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Accounting Period	12 months	Standard period for first accounts.
Current Assets	20,000	Cash + debtors, very limited liquidity.
Current Liabilities	166,500	Significant short-term obligations.
Net Current Assets (Working Capital)	(146,500)	Negative working capital, a symptom of liquidity strain.
Net Assets (Equity)	(146,500)	Negative net worth, indicating accumulated losses exceed capital.
Called-up Share Capital	1	Minimal capital raised via equity.
Number of Employees	4	Small team, typical early-stage biotech start-up.
Related Party Debt	158,591	Majority of creditors are associated companies - intercompany loans.

Interpretation of Vital Signs:

• The large negative net current assets reveal the company currently does not have sufficient liquid resources to meet short-term obligations, indicating a "symptom" of cash flow distress.
• The negative equity indicates the company has incurred losses likely due to initial R&D and operational expenses without offsetting revenues.
• The presence of significant related-party debt is common in start-ups relying on investment from parent or associated companies, but it flags dependency on external funding support.
• The small share capital and team size align with a micro-entity in a capital-intensive sector (biotechnology research).

---

3. Diagnosis: Early-Stage, Cash-Intensive Biotech Start-Up with Liquidity Strain

DLOC BIOSYSTEMS LTD is a private limited company engaged in cutting-edge biotechnology R&D (organ-on-chip technology). The company's financial profile shows typical "symptoms of distress" for an early-stage biotech venture: negative net assets and working capital, reflecting heavy upfront investment in research and product development, with no current revenue stream reported.

The financial statements indicate reliance on related-party funding (intercompany debt) to finance operations, which is a common lifeline for start-ups but exposes the company to refinancing risk if this support diminishes.

The directors have stated a going concern assumption, which suggests confidence in continued funding or future cash inflows. However, the current cash position is "weak pulse" indicating tight liquidity.

---

4. Recommendations to Improve Financial Wellness

1. Strengthen Liquidity (“Healthy Cash Flow”):

   • Secure additional equity investment or non-related third-party funding to reduce reliance on intercompany loans and improve cash reserves.
   • Explore grant funding specific to biotechnology start-ups or research tax credits in the UK to supplement cash flow.

2. Implement Cash Flow Management Controls:

   • Closely monitor and forecast cash flow to anticipate funding gaps.
   • Negotiate extended payment terms with suppliers where possible to ease short-term cash pressures.

3. Focus on Revenue Generation (“Onset of Positive Cash Flow”):

   • Accelerate commercialisation efforts for the organ-on-chip technology to develop initial customer contracts or partnerships.
   • Leverage intellectual property portfolio to attract licensing deals or joint ventures.

4. Balance Sheet Rehabilitation:

   • Plan for recapitalization to address negative equity, potentially through new share issuance or conversion of intercompany debt to equity.
   • Maintain transparent dialogue with creditors and stakeholders about financial plans and milestones.

5. Governance and Risk Management:

   • Ensure robust financial reporting and compliance with Companies Act requirements.
   • Continue to assess going concern assumptions regularly as the market and funding environment evolves.

---

Summary:
DLOC BIOSYSTEMS LTD is a typical biotech start-up facing early-stage financial challenges with negative equity and working capital deficits—symptoms of heavy investment in R&D and limited revenues. The company depends heavily on related-party funding and must focus on securing additional financing and progressing towards revenue generation to restore financial health.

---